For the year ending 2025-12-31, HROW had $25,680K increase in cash & cash equivalents over the period. $42,977K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Investment loss (gain) from investment in eton | 0 |
| Impairment of intangible assets | 0 |
| Net loss | -5,139 |
| Depreciation and amortization of property, plant and equipment and software development costs | 1,915 |
| Non-cash lease expense | 771 |
| Acquisition of melt pharmaceuticals | 4,358 |
| Provision for credit losses | 468 |
| Amortization of debt issuance costs and debt discount | 4,050 |
| Loss on disposal of equipment | -13 |
| Stock-based compensation | 12,502 |
| Accounts receivable | -5,010 |
| Inventories | 2,821 |
| Prepaid expenses and other current assets | -924 |
| Accounts payable, accrued expenses, accrued rebates and copay assistance | -4,608 |
| Accrued payroll and related liabilities | 936 |
| Deferred revenue and customer deposits | 744 |
| Amortization of intangible assets | 16,991 |
| Loss on extinguishment of debt | -7,750 |
| Net cash provided by (used in) operating activities | 43,864 |
| Net proceeds on sale of investment in eton pharmaceuticals | 0 |
| Investment in patent and trademark assets | 0 |
| Acquisition of melt pharmaceuticals | 4,358 |
| Purchase of product rights and related patents | -215 |
| Purchases of property, plant and equipment | 887 |
| Net cash used in investing activities | -5,460 |
| Net proceeds from 11.875 notes payable, net of costs | 0 |
| Net proceeds from public offering | 0 |
| Proceeds from public offering of common stock, net of offering costs | 0 |
| Proceeds from new debt, net of costs | 244,375 |
| Repayment of notes payable, inclusive of costs | 230,903 |
| Payment of payroll taxes upon vesting of psus, rsus and exercise of stock options | 25,036 |
| Proceeds from exercise of stock options | 467 |
| Payment of debt issuance costs | 1,627 |
| Net cash (used in) provided by financing activities | -12,724 |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | 25,680 |
| Net change in cash and cash equivalents | 25,680 |
| Cash and cash equivalents, beginning of period | 47,247 |
| Cash and cash equivalents, end of period | 72,927 |
HARROW, INC. (HROW)
HARROW, INC. (HROW)